ClinicalTrials.gg

Program

ABO1108

A development code.

Its studies are mostly in Chickenpox, led by Suzhou Abogen Biosciences.

Furthest: phase 3, since Sep 8, 20263 company-led studies, 3 open or runningNext primary completion: Oct 17, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suzhou Abogen Biosciences33 open or runningphase 3since Sep 8, 2026Dec 3, 2025Oct 17, 2027phase 3 · NCT07817108

Also a collaborator on its studies: abogen-biosciences-shanghai-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 3, 2025First study: phase 2 study in ChickenpoxFirst studyNCT07285278 · 300 enrolled · China
  2. Dec 3, 2025Phase 1 study in ChickenpoxNCT07285265 · 180 enrolled · China
  3. Sep 8, 2026Phase 3 study in ChickenpoxPhase 3 reachedNCT07817108 · 18,000 planned · China

Ahead

  1. Oct 17, 2027Primary completion: phase 3 study in ChickenpoxNCT07817108

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07817108Chickenpox · China3RecruitingOct 17, 202718,000
NCT07285278Chickenpox · China2Active, not recruitingMar 9, 2026300
NCT07285265Chickenpox · China1Active, not recruitingNov 6, 2025180

How it is read

Names in the registry

  • “ABO1108”, 3 entries

Codes read as this program: ABO1108.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.